New combo tested for Tough-to-Treat blood cancer
NCT ID NCT03702725
Summary
This early-stage study aimed to find a safe dose for a new three-drug combination (ibrutinib, lenalidomide, and dexamethasone) for adults with multiple myeloma that has returned or stopped responding to prior treatments. The main goal was to check for serious side effects and determine the highest dose patients could tolerate. The study involved 14 participants and was the first step in seeing if this combination could help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Loyola University Medical Center
Maywood, Illinois, 60153, United States
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
The Ohio State University Wexner Medical Center/James Cancer Hospital
Columbus, Ohio, 43210, United States
-
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157, United States
Conditions
Explore the condition pages connected to this study.